Camrelizumab With Apatinib as Neoadjuvant Therapy for Participants With Resectable Non-Small Cell Lung Cancer
Clinical trial NCT04506242 · UNKNOWN
Trial details
- NCT number
- NCT04506242
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2020-09-15
- Primary completion
- 2021-12-30
- Enrollment
- 74
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.